[CDXS] Codexis, Inc.

Overview

Type of security: Stock

Sector: Basic Industries

Industry: Major Chemicals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart CDXS

Refresh chart

Strongest Trends Summary For CDXS

CDXS is in the medium-term up 35% in 2 months. In the long-term up 277% above S&P in 2 years and up 359% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States, Europe, and Asia. It offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company also provides development services, such as enzyme screening, enzyme optimization, and enzyme services, as well as markets and sells pharmaceutical intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, it develops biocatalysts for use in various fine chemicals market segments, including food, animal feed, polymers, flavors and fragrances, and agricultural chemicals. The company sells its products through its direct sales and business development force. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.23 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 3.47% Sales Growth - Q/Q-52.1% P/E-20.87
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-44.08% ROE-84.46% ROI
Current Ratio2.33 Quick Ratio2.24 Long Term Debt/Equity Debt Ratio0.55
Gross Margin75.28% Operating Margin-52.08% Net Profit Margin-52.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-430 K Cash From Investing Activities-60 K Cash From Operating Activities-3.84 M Gross Profit5.34 M
Net Profit-5.56 M Operating Profit-5.53 M Total Assets41.42 M Total Current Assets27.63 M
Total Current Liabilities11.87 M Total Debt Total Liabilities19.8 M Total Revenue6.8 M
Technical Data
High 52 week22.57 Low 52 week8.1 Last close20.73 Last change6.09%
RSI83.52 Average true range0.91 Beta1.15 Volume24.04 K
Simple moving average 20 days20.1% Simple moving average 50 days14.32% Simple moving average 200 days29.78%
Performance Data
Performance Week22.01% Performance Month29.24% Performance Quart29.4% Performance Half50.76%
Performance Year151.27% Performance Year-to-date24.13% Volatility daily2.85% Volatility weekly6.37%
Volatility monthly13.06% Volatility yearly45.26% Relative Volume202.67% Average Volume431.77 K
New High New Low

News

2019-03-14 11:15:03 | Codexis CDXS Q4 Earnings Beat Estimates

2019-03-07 13:25:44 | Codexis, Inc. NASDAQ:CDXS Is Expected To Breakeven

2019-03-05 07:00:00 | Codexis to Participate in Two Investment Conferences in March

2019-03-02 11:48:10 | Codexis Inc CDXS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-01 07:45:00 | Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-27 21:57:23 | Edited Transcript of CDXS earnings conference call or presentation 26-Feb-19 9:30pm GMT

2019-02-27 10:18:33 | Codexis Hits the Mark in 2018, Expects Revenue to Climb 16% in 2019

2019-02-26 20:14:56 | Codexis Inc CDXS Q4 2018 Earnings Conference Call Transcript

2019-02-26 16:05:00 | Codexis Reports 2018 Fourth Quarter and Full Year Financial Results

2019-02-25 07:00:00 | Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing

2019-02-23 09:13:00 | 3 Stocks the World's Best Investors Are Buying Right Now

2019-02-19 07:00:00 | Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26

2019-02-14 07:00:00 | Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria

2019-02-06 07:00:00 | Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan

2019-02-05 16:36:19 | A Pact With Merck Sent This Biotech Stock Zooming Near A Breakout

2019-02-05 15:44:00 | Here's Why Codexis Gained as Much as 9.8% Today

2019-02-05 07:47:21 | The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

2019-02-04 16:05:00 | Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck

2019-01-30 18:00:00 | 3 Top Stocks Under $20

2019-01-14 17:04:00 | 2 Top Small-Cap Stocks to Buy in January

2019-01-02 10:55:55 | Do Institutions Own Codexis, Inc. NASDAQ:CDXS Shares?

2018-11-28 08:45:00 | Report: Developing Opportunities within Costco Wholesale, Pepsico, Northern Oil and Gas, Codexis, Sangamo Therapeutics, and BRF S.A. — Future Expectations, Projections Moving into 2018

2018-11-14 14:39:55 | This Small-Cap Biotech is Quietly Setting the Stage For a Big 2019

2018-11-13 12:11:30 | Should You Worry About Codexis Inc’s NASDAQ:CDXS CEO Pay?

2018-11-08 23:16:31 | Edited Transcript of CDXS earnings conference call or presentation 8-Nov-18 9:30pm GMT

2018-11-08 19:20:12 | Codexis CDXS Reports Break-Even Earnings for Q3

2018-11-08 18:16:49 | Codexis: 3Q Earnings Snapshot

2018-11-08 16:05:00 | Codexis Reports Third Quarter 2018 Financial Results

2018-11-08 07:00:00 | Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114

2018-11-07 16:05:00 | Codexis to Present at Two Investment Conferences in November

2018-11-01 11:28:03 | Will Codexis CDXS Report Negative Earnings Next Week? What You Should Know

2018-11-01 07:00:00 | Codexis to Hold Third Quarter 2018 Conference Call on November 8

2018-10-17 07:20:00 | Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis — Discovering Underlying Factors of Influence

2018-10-06 08:35:00 | Better Synthetic Biology Stock: Amyris vs. Codexis

2018-10-01 07:00:00 | Codexis Appoints Claus Ladefoged to Global Enzyme Business Development Role

2018-09-11 07:11:11 | The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor

2018-09-10 09:23:01 | 5 Top-Ranked Nasdaq Stocks Defying the Worst September Start

2018-09-05 14:33:36 | Codexis Inc NASDAQ:CDXS: Did It Outperform The Industry?

2018-09-04 15:31:00 | Here's Why Codexis Gained 19.4% in August

2018-08-29 07:00:00 | Codexis to Present at Three Investment Conferences in September

2018-08-22 17:55:15 | Edited Transcript of CDXS earnings conference call or presentation 8-Aug-18 8:30pm GMT

2018-08-20 08:10:00 | Report: Exploring Fundamental Drivers Behind Codexis, Kornit Digital, NewLink Genetics, NCS Multistage, Mountain Province Diamonds, and CSS Industries — New Horizons, Emerging Trends, and Upcoming Developments

2018-08-17 12:50:00 | 4 Under-the-Radar Small Cap Stars

2018-08-15 09:58:01 | E-commerce, Favorable Markets Drive Growth at Grainger GWW

2018-08-08 20:55:12 | Codexis CDXS Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 19:48:39 | Codexis: 2Q Earnings Snapshot

2018-08-08 16:05:00 | Codexis Reports Second Quarter 2018 Financial Results

2018-08-08 14:30:00 | Codexis, Inc. to Host Earnings Call

2018-08-01 07:00:00 | Codexis to Hold Second Quarter 2018 Conference Call on August 8

2018-07-11 07:00:00 | Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development